^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Ovarian Serous Adenocarcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    07/13/2022
    Excerpt:
    Low-Grade Serous Carcinoma, Recurrence Therapy: Dabrafenib + trametinib (for BRAF V600E-positive tumors) was added as a category 2A recommendation.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Excerpt:
    TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.